<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667196</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV 2017-07</org_study_id>
    <nct_id>NCT03667196</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions</brief_title>
  <acronym>STRIKE-CTO</acronym>
  <official_title>Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions; Systemic Chronic Total Occlusion Revascularization Korea Research-Chronic Total Occlusion (STRIKE-CTO) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Whan Lee, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to 1) analyze the clinical, anatomical and periprocedural
      differences of patients who underwent a procedure related to coronary CTO through the
      antergrade approach and retrograde approach; 2) analyze the success rate of the procedures
      and the incidence and patterns of complications; 3) compare and analyze long-term
      performances after the successful procedure; and 4) identify the independent factors that
      require a retrograde approach and the prognostic factor regarding long-term performances
      after use of each approach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>12-month after PCI</time_frame>
    <description>Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>12-month after PCI</time_frame>
    <description>the periprocedural myocardial infarction under the SCAI definition or the non-lethal myocardial infarction during the follow-up observations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the complex endpoints of target vessel revascularization/reocclusion occurrence</measure>
    <time_frame>12-month after PCI</time_frame>
    <description>including chronic total occlusion and angiostenosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure success rate</measure>
    <time_frame>every 1-year up-to 5-year</time_frame>
    <description>A procedure success defined as the case where a final vessel diameter stenosis &lt; 30% is achieved after the stent insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>every 1-year up-to 5-year</time_frame>
    <description>Q-wave VS non-Q-wave, periprocedural myocardial infarction VS follow-up myocardial infarction (spontaneous myocardial infarction</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antegrade and retrograde approach</intervention_name>
    <description>This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject selection will be determined after screening patients who undergo PCI for CTO
        lesions and completing the evaluation of all inclusion/exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged&gt;20

          -  Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5
             mm in blood vessel diameter

          -  Patients who have symptoms of angina or objectively proven myocardial ischemia
             (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment
             elevation myocardial infarction)

          -  Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or
             let their representative do this), and signed the informed consent form approved by
             the IRB of each study institute

        Exclusion Criteria:

          -  Patients who are pregnant or lactating or have childbearing potential Patients in whom
             contrast medium and heparin are contraindicated or who are hypersensitive to them

          -  Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are
             contraindicated

          -  Patients scheduled to undergo a surgery, etc. that requires discontinuance of an
             antiplatelet drug within 12 months after participation in the study

          -  Acute ST elevation myocardial infarction at the time of hospitalization

          -  Terminally ill patients with their life expectancy &lt; one year

          -  Patients who have serious diseases other than cardiac diseases that may affect
             limitation of residual life time or observation of the protocol (e.g.
             oxygen-independent chronic obstructive pulmonary disease, persisting hepatitis or
             serious hepatic insufficiency, severe renal disease, etc. Be left up to the discretion
             of the investigator.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <phone>8210-6678-1376</phone>
      <email>hearthsk@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Sool Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JON Suh, MD</last_name>
      <phone>8210-3407-3843</phone>
      <email>immanuel@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>JON Suh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Hwan Lee, MD</last_name>
      <phone>8210-9213-8237</phone>
      <email>myheart@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Hwan Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangwon National University Hospital</name>
      <address>
        <city>Gangwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Ki Lee, MD</last_name>
      <phone>8210-6373-9290</phone>
      <email>mdbklee@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Bong-Ki Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul national university Bundang hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Hwan Yoon, MD</last_name>
      <phone>8210-2336-9000</phone>
      <email>changhwanyoon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chang-Hwan Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Hyun Yang, MD</last_name>
      <phone>8210-4590-5067</phone>
      <email>yangthmd@naver.com</email>
    </contact>
    <investigator>
      <last_name>Han-Young Jin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su-Hong Kim, MD</last_name>
      <phone>8210-2571-2149</phone>
      <email>dhugie@naver.com</email>
    </contact>
    <investigator>
      <last_name>Su-Hong Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Whan Lee, MD</last_name>
      <phone>8210-7398-9897</phone>
      <email>seungwlee@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Whan Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Young Lee, MD</last_name>
      <phone>8210-2507-4780</phone>
      <email>jyleeheart@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Young Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veterans Hospital Service Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Hoon Lee, MD</last_name>
      <phone>8210-5551-7867</phone>
      <email>changhoon.lee121@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chang-Hoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyung-Min, Park</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyung-Min Park, MD</last_name>
      <phone>8210-9995-8684</phone>
      <email>min8684@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Gyung-Min Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Whan Lee, M.D., Ph.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

